At the molecular level, transcriptomic profiling of a single nucleus RNA-seq dataset of renal epithelial cells revealed ...
A phase 2 trial supports SBRT for primary treatment of localized RCC. Stereotactic body radiotherapy (SBRT) showed favorable long-term local control and cause-specific survival (CSS) in a phase 2 ...
Incidence and mortality from renal cancer may double by 2050, according to a study published in European Urology.
In a city, coworking hubs bring people and ideas together. Inside cancer cells, similar hubs form—but instead of fueling ...
As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...
Many medicines are available to treat kidney cancer. If one treatment doesn’t help or stops working, your health care provider may recommend another option. If you or a loved one has kidney cancer and ...
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows ...
Newspoint on MSN
5 Major Signs of Kidney Cancer You Must Know
Kidney cancer often goes unnoticed compared to more widely discussed cancers such as breast, skin, or prostate cancer. The ...
KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of ...
Prospective evidence supports SABR as a valid option for localized RCC and suggests SABR with or without immunotherapy has promise in the metastatic setting. Challenging notions of renal cell ...
If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback